With the current study, we confirm the observation made by Nauck et al. [3] in 1986 that the incretin effect is reduced in patients with type 2 diabetes, and we conclude that this deficiency is most ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Incretin-based therapies are continuing to evolve with ...

An international research group has clarified the action mechanism of incretin-based drugs in the treatment of diabetes. The research group headed by Professor SEINO Susumu included Researcher Okechi ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The FDA announced it approved the injectable dual ...

With a broad research focus on heart disease risk reduction through the development of novel treatment strategies, Stephen Nicholls, MBBS, PhD, Monash University and Victorian Heart Hospital, ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its blockbuster molecule tirzepatide. Now, with a pipeline chock-full of numerous ...

In a large U.S. retrospective cohort study published in JAMA Network Open, investigators report that glucagon-like peptide-1 ...

We aimed to investigate whether the reduced incretin effect observed in patients with type 2 diabetes is a primary event in the pathogenesis of type 2 diabetes or a consequence of the diabetic state.